Aplastic Anemia (AA)

Categories: Blood diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Aplastic Anemia

MalaCards integrated aliases for Aplastic Anemia:

Name: Aplastic Anemia 57 12 75 53 59 74 37 29 13 6 43 15 38 63 72
Aplastic Anemia, Susceptibility to 57 6
Idiopathic Aplastic Anemia 53 59
Secondary Aplastic Anemia 53 72
Anemia Aplastic 53 55
Idiopathic Bone Marrow Failure 59
Aplastic Anemia, Idiopathic 72
Aplastic Anemia Idiopathic 53
Anemia, Aplastic 44
Aa 74


Orphanet epidemiological data:

idiopathic aplastic anemia
Age of onset: Adult; Age of death: adult;


External Ids:

Disease Ontology 12 DOID:12449
OMIM 57 609135
KEGG 37 H01132
ICD9CM 35 284.9
MeSH 44 D000741
NCIt 50 C2870
SNOMED-CT 68 79000000
MESH via Orphanet 45 C538494
ICD10 via Orphanet 34 D61.0 D61.1 D61.2 more
UMLS via Orphanet 73 C0348890
UMLS 72 C0002874 C0271908 C0348890

Summaries for Aplastic Anemia

NIH Rare Diseases : 53 Aplastic anemia is a blood disorder caused by failure of the bone marrow to make enough new blood cells. Bone marrow is a sponge-like tissue inside the bones that makes stem cells that develop into red blood cells, white blood cells, and platelets. Symptoms may include fatigue, weakness, dizziness, shortness of breath, frequent infections, and bleeding. Aplastic anemia can lead to other health concerns such as an irregular heartbeat, an enlarged heart, and heart failure. It can be caused by injury to blood stem cells due to exposure to certain drugs, chemotherapy, congenital disorders, drug therapy to suppress the immune system, pregnancy, radiation therapy, or toxins such as benzene or arsenic. When the cause is unknown, it is referred to as idiopathic aplastic anemia. In about half of all cases, no cause can be found. The blood disorder can be acute or chronic. Treatment may consist of supportive care only, blood transfusions, medicines to suppress the immune system, or hematopoietic cell transplantation. The British Committee for Standards in Haematology recommends treating infection or uncontrolled bleeding before administering immunosuppressive therapy, including in patients scheduled for HCT. In the presence of severe infection, however, it may be necessary to proceed directly to HCT to provide the patient with the best chance for early neutrophil recovery. The Pediatric Haemato-Oncology Italian Association recommends HCT from a matched sibling donor for severe aplastic anemia, and if a matched donor is not available, options include immunosuppressive therapy or unrelated donor HCT. Approximately one third of patients with aplastic anemia do not respond to immunosuppression. The thrombopoietin-receptor agonist eltrombopag is approved for use in patients with severe aplastic anemia who fail to respond adequately to immunosuppressive therapy. Independent of response or degree of response, risks include relapse and late-onset clonal disease, such as paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome (MDS), or leukemia. [14, 38, 39, 40, 41] Pregnant women with aplastic anemia have a 33% risk of relapse. Provide supportive care in these patients, maintain the platelet count above 20 ? 109/L, if possible, and consider administering cyclosporine. Note that monotherapy with hematopoietic growth factors (eg, recombinant human erythropoietin [rHuEPO], granulocyte colony-stimulating factor [G-CSF]) is not recommended for newly diagnosed patients. Frequent outpatient follow-up for patients with aplastic anemia is needed to monitor blood counts and any adverse effects of various drugs. Transfusions of packed red blood cells (RBCs) and platelets are administered on an outpatient basis.

MalaCards based summary : Aplastic Anemia, also known as aplastic anemia, susceptibility to, is related to deficiency anemia and paroxysmal nocturnal hemoglobinuria, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Aplastic Anemia is SBDS (SBDS Ribosome Maturation Factor), and among its related pathways/superpathways are Osteoclast differentiation and Antigen processing and presentation. The drugs Radium Ra 223 dichloride and Posaconazole have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are anemia and aplastic anemia

Disease Ontology : 12 An anemia that is characterized by a deficiency of red blood cells, white blood cells and platelets produced by bone marrow.

OMIM : 57 Aplastic anemia is a serious disorder of the bone marrow that affects between 2 and 5 persons per million per year. About 75% of these cases are classified as idiopathic (Young, 2000). In about 15% of cases a drug or infection can be identified that precipitates the aplasia, although why only some individuals are susceptible is unclear. In about 5 to 10% of patients, the aplastic anemia is constitutional--i.e., is familial or presents with one or more associated somatic abnormalities (summary by Vulliamy et al., 2002). (609135)

MedlinePlus : 43 Aplastic anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. There are different types, including Fanconi anemia. Causes include Toxic substances, such as pesticides, arsenic, and benzene Radiation therapy and chemotherapy for cancer Certain medicines Infections such as hepatitis, Epstein-Barr virus, or HIV Autoimmune disorders Certain inherited conditions Pregnancy In many people, the cause is unknown. Symptoms include fatigue, weakness, dizziness, and shortness of breath. It can cause heart problems such as an irregular heartbeat, an enlarged heart, and heart failure. You may also have frequent infections and bleeding. Your doctor will diagnose aplastic anemia based on your medical and family histories, a physical exam, and test results. Once your doctor knows the cause and severity of the condition, he or she can create a treatment plan for you. Treatments include blood transfusions, blood and marrow stem cell transplants, and medicines. NIH: National Heart, Lung, and Blood Institute

KEGG : 37
Aplastic anemia (AA) is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. Most cases of acquired aplastic anemia are the consequence of an immune-mediated destruction of hematopoiesis. Autoreactive cytotoxic T cells play a key role in the pathogenesis of AA by myelosuppressive cytokines including interferon-gamma. It has been reported that polymorphisms in IFNG are related to AA. A minority of patients with AA has heterozygous mutations in genes encoding the telomerase components TERT or TERC. Immunosuppressive therapy (IST) is one of the main treatment modalities for AA, although most patients with telomerase mutations do not respond adequately to IST.

UniProtKB/Swiss-Prot : 74 Aplastic anemia: A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements. It is characterized by peripheral pancytopenia and marrow hypoplasia.

PubMed Health : 63 About aplastic anemia: Aplastic anemia (a-PLAS-tik uh-NEE-me-uh) is a blood disorder in which the body's bone marrow doesn't make enough new blood cells. Bone marrow is a sponge-like tissue inside the bones. It makes stem cells that develop into red blood cells, white blood cells, and platelets (PLATE-lets). Red blood cells carry oxygen to all parts of your body. They also carry carbon dioxide (a waste product) to your lungs to be exhaled. White blood cells help your body fight infections. Platelets are blood cell fragments that stick together to seal small cuts or breaks on blood vessel walls and stop bleeding. It's normal for blood cells to die. The lifespan of red blood cells is about 120 days. White blood cells live less than a day. Platelets live about 6 days. As a result, your bone marrow must constantly make new blood cells. If your bone marrow can't make enough new blood cells, many health problems can occur. These problems include irregular heartbeats called arrhythmias (ah-RITH-me-ahs), an enlarged heart, heart failure, infections, and bleeding. Severe aplastic anemia can even cause death.

Wikipedia : 75 Aplastic anemia is an autoimmune disease in which the body fails to produce blood cells in sufficient... more...

Related Diseases for Aplastic Anemia

Diseases in the Aplastic Anemia family:

Rare Acquired Aplastic Anemia

Diseases related to Aplastic Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 984)
# Related Disease Score Top Affiliating Genes
1 deficiency anemia 34.1 THPO IL3 EPO
2 paroxysmal nocturnal hemoglobinuria 34.1 PIGA CD59 CD55
3 dyskeratosis congenita 33.8 TINF2 TERT TERC NOP10 NHP2 DKC1
4 revesz syndrome 33.7 TINF2 TERT TERC NOP10 DKC1
5 fanconi anemia, complementation group a 33.6 THPO TERC NBN KITLG IL3 DKC1
6 shwachman-diamond syndrome 1 33.6 SBDS RPL5 DKC1
7 dyskeratosis congenita, autosomal recessive 1 33.3 TERT NOP10 NHP2
8 hemoglobinuria 32.7 PIGA EPO CD59 CD55
9 pancytopenia 32.7 THPO TERT IL3 EPO DKC1 CSF2
10 myelodysplastic syndrome 32.4 THPO TERT TERC SBDS PIGA KITLG
11 leukemia, acute myeloid 32.3 THPO TERT KITLG IL3 CSF2
12 hemolytic anemia 32.0 PIGA EPO CD59 CD55
13 inherited bone marrow failure syndromes 32.0 TERT TERC SBDS
14 mucormycosis 31.8 IFNG CSF2
15 lymphopenia 31.8 IFNG CD59 CD55
16 leukemia, chronic myeloid 31.8 THPO KITLG IL3 EPO CSF2
17 acquired immunodeficiency syndrome 31.7 IFNG EPO CSF2
18 large granular lymphocyte leukemia 31.6 IFNG CSF2
19 polycythemia 31.6 THPO KITLG IL3 EPO
20 hypersplenism 31.5 THPO IFNG EPO
21 transient erythroblastopenia of childhood 31.5 KITLG EPO
22 dyskeratosis congenita, autosomal dominant 1 31.5 TINF2 TERT TERC DKC1
23 polycythemia vera 31.4 THPO KITLG IL3 EPO
24 allergic hypersensitivity disease 31.4 KITLG IL3 IFNG
25 diamond-blackfan anemia 31.3 THPO RPL5 KITLG IL3 EPO CSF2
26 severe congenital neutropenia 31.2 KITLG IL3 CSF2
27 sarcoidosis 1 31.2 IL3 IFNG CSF2
28 paroxysmal nocturnal hemoglobinuria 1 31.1 TERC PIGA
29 trichosporonosis 31.0 IFNG CSF2
30 lymphoma, non-hodgkin, familial 31.0 PRF1 NBN IL3 CSF2 CD59
31 hematologic cancer 31.0 THPO KITLG IL3 CSF2
32 miliary tuberculosis 30.9 IFNG EPO
33 cyclic neutropenia 30.9 KITLG IL3 IFNG CSF2
34 pulmonary fibrosis 30.9 TINF2 TERT TERC
35 felty syndrome 30.5 IL3 CSF2
36 amyloidosis aa 12.7
37 helsmoortel-van der aa syndrome 12.7
38 retinopathy aplastic anemia neurological abnormalities 12.4
39 rare acquired aplastic anemia 12.4
40 rare constitutional aplastic anemia 12.4
41 congenital hypoplastic anemia 12.2
42 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 12.2
43 alopecia areata 12.2
44 bone marrow failure syndrome 1 12.2
45 adnp syndrome 12.0
46 aarskog-scott syndrome 12.0
47 dyskeratosis congenita, autosomal dominant 6 12.0
48 williams-beuren region duplication syndrome 11.8
49 dyskeratosis congenita, autosomal dominant 2 11.7
50 pulmonary fibrosis and/or bone marrow failure, telomere-related, 1 11.7

Graphical network of the top 20 diseases related to Aplastic Anemia:

Diseases related to Aplastic Anemia

Symptoms & Phenotypes for Aplastic Anemia

Human phenotypes related to Aplastic Anemia:

59 32 (show all 13)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 anemia 59 32 obligate (100%) Obligate (100%) HP:0001903
2 aplastic anemia 32 obligate (100%) HP:0001915
3 bone marrow hypocellularity 59 32 hallmark (90%) Very frequent (99-80%) HP:0005528
4 pancytopenia 59 32 frequent (33%) Frequent (79-30%) HP:0001876
5 reticulocytopenia 59 32 frequent (33%) Frequent (79-30%) HP:0001896
6 gingival bleeding 59 32 occasional (7.5%) Occasional (29-5%) HP:0000225
7 thrombocytopenia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001873
8 recurrent infections 59 32 occasional (7.5%) Occasional (29-5%) HP:0002719
9 epistaxis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000421
10 neutropenia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001875
11 retinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0000573
12 ecchymosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0031364
13 autoimmune antibody positivity 59 Excluded (0%)

Clinical features from OMIM:


UMLS symptoms related to Aplastic Anemia:

angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Aplastic Anemia:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.24 CD55 CD59 CSF2 DKC1 EPO IFNG
2 cellular MP:0005384 10.23 CD59 CSF2 DKC1 EPO IFNG KITLG
3 endocrine/exocrine gland MP:0005379 10.06 CD59 CSF2 IFNG KITLG NBN PRF1
4 immune system MP:0005387 10.06 CSF2 DKC1 EPO IFNG KITLG NBN
5 embryo MP:0005380 10.03 CSF2 DKC1 EPO IFNG KITLG NBN
6 mortality/aging MP:0010768 9.97 CD59 CSF2 DKC1 EPO IFNG KITLG
7 integument MP:0010771 9.86 CSF2 DKC1 EPO IFNG KITLG PIGA
8 neoplasm MP:0002006 9.56 CSF2 DKC1 IFNG KITLG NBN PIGA
9 reproductive system MP:0005389 9.32 CD59 CSF2 DKC1 IFNG KITLG NBN

Drugs & Therapeutics for Aplastic Anemia

PubMed Health treatment related to Aplastic Anemia: 63

Treatments for aplastic anemia include blood transfusions, blood and marrow stem cell transplants, and medicines. These treatments can prevent or limit complications, relieve symptoms, and improve quality of life. Blood and marrow stem cell transplants may cure the disorder in some people who are eligible for a transplant. Removing a known cause of aplastic anemia, such as exposure to a toxin, also may cure the condition.

Drugs for Aplastic Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 227)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Radium Ra 223 dichloride Approved, Investigational Phase 4 444811-40-9
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
Sodium citrate Approved, Investigational Phase 4 68-04-2
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
12 14-alpha Demethylase Inhibitors Phase 4
13 Steroid Synthesis Inhibitors Phase 4
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15 Antiparasitic Agents Phase 4
16 Antiprotozoal Agents Phase 4
17 Calcium, Dietary Phase 4
18 Anticoagulants Phase 4
19 Citrate Phase 4
20 Hematinics Phase 4
21 Ferric Compounds Phase 4
22 Vitamins Phase 4
23 Hydroxycholecalciferols Phase 4
24 Vitamin D2 Phase 4
25 Ergocalciferols Phase 4
26 Calciferol Phase 4
27 Chelating Agents Phase 4
28 Nutrients Phase 4
29 Iron Chelating Agents Phase 4
30 Micronutrients Phase 4
31 Trace Elements Phase 4
Sirolimus Approved, Investigational Phase 3 53123-88-9 6436030 5284616 46835353
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 3 62-90-8 229455
Nandrolone decanoate Approved, Illicit Phase 3 360-70-3 9677
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
Daunorubicin Approved Phase 3 20830-81-3 30323
Idarubicin Approved Phase 3 58957-92-9 42890
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
Iodine Approved, Investigational Phase 3 7553-56-2 807
Thioguanine Approved Phase 3 154-42-7 2723601
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
Lenograstim Approved, Investigational Phase 3 135968-09-1
tannic acid Approved Phase 3 1401-55-4
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337

Interventional clinical trials:

(show top 50) (show all 362)
# Name Status NCT ID Phase Drugs
1 Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia Unknown status NCT01995331 Phase 4 cyclophosphamide,cyclosporine A
2 Different Doses of Anti-thymocyte Globin With 2.5 or 3.75mg/kg to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
3 Multi-center Clinical Study of Immunosuppressants, Cyclophosphamide, And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia Unknown status NCT02838992 Phase 4 Rabbit ATG, (Genzyme);Cy;CsA
4 Child With Severe Aplastic Anemia (SAA) Therapy: the Injection of Umbilical Cord Derived Mesenchymal Stem Cells. Unknown status NCT02218437 Phase 4 MSC+ATG
5 A Single Arm, Multicenter, Open Label Study of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia Completed NCT01546415 Phase 4 Desferasirox
6 An Epidemiological Study to Assess the Prevalence of Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) Completed NCT01736540 Phase 4
7 Randomized Clinical Trial of the Use of Eltrombopag in Children With Idiopathic Aplastic Anemia Recruiting NCT03243656 Phase 4 Eltrombopag
8 The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia Recruiting NCT02745717 Phase 4 Thymoglobulin;Cyclosporine Oral Product
9 Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia Recruiting NCT03896971 Phase 4 Combination of thrombopoietin mimetic and cyclosporin A
10 A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride Recruiting NCT02312960 Phase 4
11 Incidence of Invasive Fungal Disease in Patients Receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis Active, not recruiting NCT02875743 Phase 4 Posaconazole
12 Effect of Auryxia on ESA Utilization in ESRD Patients With High Ferritin & Low Transferrin Saturation: A Pilot Project Active, not recruiting NCT03055598 Phase 4 Ferric Citrate
13 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Enrolling by invitation NCT03176849 Phase 4
14 Open-label Study of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Undergoing Treatment Programs in Comparison With Control Group Terminated NCT01818726 Phase 4 ICL670;Chelation;No chelation
15 A Prospective Randomized Multicenter Study Comparing Different Dosages of Rabbit Antithymocyte Globulin (Thymoglobuline) in Patients With Severe Aplastic Anemia Unknown status NCT01844635 Phase 3 Thymoglobulin
16 Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition to Anti-thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Adult Acquired Aplastic Anemia Unknown status NCT01145976 Phase 3 Cy-ATG;Flu-ATG
17 The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population Unknown status NCT02393508 Phase 3
18 A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study Unknown status NCT02173951 Phase 2, Phase 3 Deferiprone
19 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
20 Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders Completed NCT00000597 Phase 3 antilymphocyte serum;nandrolone
21 Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia Completed NCT00004474 Phase 3 Anti-thymocyte globulin;Cyclophosphamide
22 Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia Completed NCT00455312 Phase 2, Phase 3 Campath 1H;Cyclophosphamide;Fludarabine;antithymocyte globulin;Methylprednisolone
23 Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition To Anti-Thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome Completed NCT00774527 Phase 3 Cyclophosphamide-fludarabine-anti thymocyte globulin
24 A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
25 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
26 Antithymocyte Globulin (ATG) and Cyclosporine (CSA) to Treat Patients With Myelodysplastic Syndrome (MDS). A Randomized Trial Comparing ATG + CSA With Best Supportive Care Completed NCT00004208 Phase 3 ATG + CSA
27 A Prospective Randomized Study Comparing Rapamune and Tacrolimus vs. Cyclosporine and Methotrexate as Immune Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation, Using HLA-A, -B, -DRβ1 Identical Related or Unrelated Donors. A Nordic Multicenter Study. Completed NCT00993343 Phase 3 Sirolimus/tacrolimus;cyclosporine/methotrexate
28 A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT00098280 Phase 3 Eculizumab
29 High Dose Cyclophosphamide for Treatment of Systemic Sclerosis (Scleroderma) Completed NCT00501995 Phase 3 IV Cyclophosphamide
30 Efficacy and Safety of Thrombopoetin-Receptor Agonist Eltrombopag in in Combination With Ciclosporin A in Moderate Aplastic Anemia (EMAA): Prospective Randomized Multicenter Study Recruiting NCT02773225 Phase 2, Phase 3 Eltrombopag;Placebo (for Eltrombopag)
31 A Phase II Multicenter Randomized Study of Eltrombopag Combined With Cyclosporine and hATG Versus hATG and CsA as First Line Treatment in Pediatric Patients With Severe Acquired Aplastic Anemia Recruiting NCT03413306 Phase 3 Eltrombopag;IST (ATG + CsA)
32 Randomized Multicenter Trial of Two Transfusion Strategies for Patient Receiving Chemotherapy for Acute Leukemia or Hematopoietic Stem Cells With Medico-economic Evaluation of Cost Minimization. Recruiting NCT02461264 Phase 3 Single red blood packed cells Transfusion;Two packed red blood cells Transfusion
33 Phase 2/3 Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia Refractory to or Ineligible for Immunosuppressive Therapy Active, not recruiting NCT02773290 Phase 2, Phase 3
34 A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients. Active, not recruiting NCT02099747 Phase 3 hATG;CsA;Eltrombopag
35 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
36 A Phase III Multicenter Randomized Study of Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia Not yet recruiting NCT03825744 Phase 3 Hetrombopag Olamine+Standard Therapy;Placebo+Standard Therapy
37 A Phase 2/3 Study of AMG531 in Patients With Aplastic Anemia PreviouslyUntreated With Immunosuppressive Therapy Not yet recruiting NCT03957694 Phase 2, Phase 3 Romiplostim
38 Outcome of Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin (ATG ) Conditioning Regimens in Severe Aplastic Anemia Patients Not yet recruiting NCT03295058 Phase 2, Phase 3 Non ATG Conditioning regimen;GVHD Prophylaxis;ATG conditioning regimen
40 A Randomized Controlled Crossover Trial of Two Different Central Venous Catheter Flushing Schemes in Pediatric Hematology and Oncology Patients in Alberta, Canada Terminated NCT01343680 Phase 3 Heparin;Normal saline
41 A Randomized, Double-blind, Placebo-controlled, Phase III, Multi-centre Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With IPSS Intermediate-1, Intermediate 2 and High-risk Myelodysplastic Syndromes (MDS) SUPPORT: A StUdy of eltromboPag in myelodysPlastic SyndrOmes Receiving azaciTidine Terminated NCT02158936 Phase 3 Eltrombopag;Azacitidine;Placebo;Placebo
42 Phase I/II Study of An Ex Vivo Immunotherapy for Treatment of Idiopathic Aplastic Anemia Unknown status NCT00399971 Phase 1, Phase 2 Ex vivo immunotherapy
43 Phase I/II Study of Fludarabine, Cyclophosphamide Plus TBI Conditioning Regimen for Double Units Cord Blood Transplantation in Severe Aplastic Anemia Unknown status NCT00881933 Phase 1, Phase 2
44 Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Bone Marrow (or Mobilized Peripheral Blood) Transplantation in Severe Aplastic Anemia Unknown status NCT00737685 Phase 2 cyclophosphamide, fludarabine , thymoglobulin
45 Haploidentical Stem Cell Transplantation With Fixed Dose of T Cells After in Vitro T Cell Depletion Using CD3 Monoclonal Antibody for Children With Acquired Severe Aplastic Anemia Unknown status NCT01759732 Phase 2 Fludarabine;Cyclophosphamide
46 Reduced Toxicity Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia Unknown status NCT00882323 Phase 2 Cyclophosphamide, Fludarabine, Thymoglobulin
47 PhaseⅠ/ⅡTrial of Bone Marrow Derived Mesenchymal Stem Cell Transplantation From Related Donor to Patients With Relapsed/Refractory Aplastic Anemia. Unknown status NCT01305694 Phase 1, Phase 2
48 A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia Unknown status NCT00319878 Phase 1, Phase 2 Sirolimus;Cyclosporine
49 A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia Unknown status NCT02203396 Phase 2 rabbit ATG, Cyclosporine, Levamisole
50 Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat SAA Unknown status NCT01182662 Phase 2

Search NIH Clinical Center for Aplastic Anemia

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Aplastic Anemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: anemia, aplastic

Genetic Tests for Aplastic Anemia

Genetic tests related to Aplastic Anemia:

# Genetic test Affiliating Genes
1 Aplastic Anemia 29 IFNG NBN PRF1 SBDS TERT

Anatomical Context for Aplastic Anemia

MalaCards organs/tissues related to Aplastic Anemia:

Bone, Bone Marrow, T Cells, Heart, Myeloid, Liver, Lung

Publications for Aplastic Anemia

Articles related to Aplastic Anemia:

(show top 50) (show all 7816)
# Title Authors PMID Year
Mutations in the SBDS gene in acquired aplastic anemia. 9 38 8 71
17478638 2007
First case of aplastic anemia in a Japanese child with a homozygous missense mutation in the NBS1 gene (I171V) associated with genomic instability. 9 38 8 71
15338273 2004
Perforin gene mutations in patients with acquired aplastic anemia. 38 8 71
17311987 2007
Homozygosis for (12) CA repeats in the first intron of the human IFN-gamma gene is significantly associated with the risk of aplastic anaemia in Caucasian population. 9 8 71
15327519 2004
Association between aplastic anaemia and mutations in telomerase RNA. 8 71
12090986 2002
Telomerase mutations in families with idiopathic pulmonary fibrosis. 9 38 71
17392301 2007
Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. 9 38 71
15814878 2005
Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. 38 71
21436073 2011
Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. 9 71
14630445 2003
Wilms' tumor 1 mRNA expression: a good tool for differentiating between myelodysplastic syndrome and aplastic anemia in children? 38 17
31210595 2019
Abnormal expression of b10 cell frequencies: possible relation to pathogenesis and disease severity of aplastic anemia. 38 17
31166440 2019
Pulmonary fibrosis, bone marrow failure, and telomerase mutation. 71
22512499 2012
Ancestral mutation in telomerase causes defects in repeat addition processivity and manifests as familial pulmonary fibrosis. 71
21483807 2011
Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. 71
19760749 2009
Short telomeres are a risk factor for idiopathic pulmonary fibrosis. 71
18753630 2008
Complex inheritance pattern of dyskeratosis congenita in two families with 2 different mutations in the telomerase reverse transcriptase gene. 71
18042801 2008
Adult-onset pulmonary fibrosis caused by mutations in telomerase. 71
17460043 2007
Hematologic abnormalities in Shwachman Diamond syndrome: lack of genotype-phenotype relationship. 71
15769891 2005
Novel SBDS mutations caused by gene conversion in Japanese patients with Shwachman-Diamond syndrome. 71
14749921 2004
Mutations in SBDS are associated with Shwachman-Diamond syndrome. 71
12496757 2003
Association between a high-expressing interferon-gamma allele and a lower frequency of kidney angiomyolipomas in TSC2 patients. 71
12192641 2002
Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). 71
11325820 2001
DNA requirement in FANCD2 deubiquitination by USP1-UAF1-RAD51AP1 in the Fanconi anemia DNA damage response. 17
31253762 2019
Perioperative management for a patient with chronic pancytopenia: a case of aplastic anemia with persistent neutropenia following preoperative administration of G-CSF. 9 38
20094735 2010
Mechanisms of adverse drug reactions to biologics. 9 38
20020272 2010
Downregulation of GATA-2 and overexpression of adipogenic gene-PPARgamma in mesenchymal stem cells from patients with aplastic anemia. 9 38
19772889 2009
Changes in cytokine profile pre- and post-immunosuppression in acquired aplastic anemia. 9 38
19586939 2009
[Detection of putative T cell clones using T cell receptor beta chain gene clonality assay in Korean patients with aplastic anemia]. 9 38
19726886 2009
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. 9 38
19242494 2009
Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. 9 38
19336743 2009
Lymphocytes with aberrant expression of Fas or Fas ligand attenuate immune bone marrow failure in a mouse model. 9 38
19265119 2009
NOLA1 gene mutations in acquired aplastic anemia. 9 38
18989882 2009
Anti-moesin antibodies in the serum of patients with aplastic anemia stimulate peripheral blood mononuclear cells to secrete TNF-alpha and IFN-gamma. 9 38
19109204 2009
Transfusion-related acute lung injury (TRALI) induced by donor-derived anti-HLA antibodies in aplastic anemia: possible priming effect of granulocyte-colony stimulating factor (G-CSF) on the recipient neutrophils. 9 38
19915300 2009
Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies. 9 38
18727660 2009
Comparison on in vitro characterization of fucospheres and chitosan microspheres encapsulated plasmid DNA (pGM-CSF): formulation design and release characteristics. 9 38
19859814 2009
Transient severe pancytopenia due to elevated tumor necrosis factor-alpha in overwhelming infection. 9 38
19293548 2009
Acquired aplastic anemia: correlation between etiology, pathophysiology, bone marrow histology and prognosis factors. 9 38
19942964 2009
[Expression of hematopoietic cytokines EPO, SCF and GM-CSF in bone marrow cells of patients with chronic aplastic anemia]. 9 38
18928604 2008
Disease-associated human telomerase RNA variants show loss of function for telomere synthesis without dominant-negative interference. 9 38
18710936 2008
Telomere maintenance and human bone marrow failure. 9 38
18239083 2008
Aplastic anemia. 9 38
18391779 2008
[Single nucleotide polymorphism of interferon-gamma gene +874 T/A in patients with aplastic anemia]. 9 38
18426658 2008
[Immune pathophysiology of refractory anemias]. 9 38
18326316 2008
[Paroxysmal nocturnal hemoglobinuria (PNH)]. 9 38
18330025 2008
[The polymorphism of interferon gamma gene CA short tandem repeat is associated with aplastic anemia]. 9 38
18390192 2008
[Clinical implications of combined measurement bone marrow T cells intracellular IFNgamma and HLA-DRB1*1501 measurement in predicting the response to immunosuppressive therapy for aplastic anemia]. 9 38
18218241 2007
Treatment of acquired severe aplastic anemia with antilymphocyte globulin, cyclosporin A, methyprednisolone, and granulocyte colony-stimulating factor. 9 38
17506070 2007
Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. 9 38
17526862 2007
Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. 9 38
17663679 2007

Variations for Aplastic Anemia

ClinVar genetic disease variations for Aplastic Anemia:

6 (show top 50) (show all 105)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 RPL5 NM_000969.5(RPL5): c.74-1G> C single nucleotide variant Pathogenic rs1553284997 1:93299101-93299101 1:92833544-92833544
2 SBDS NM_016038.4(SBDS): c.258+2T> C single nucleotide variant Pathogenic rs113993993 7:66459197-66459197 7:66994210-66994210
3 TERC NR_001566.1(TERC): n.72C> G single nucleotide variant Pathogenic rs199422265 3:169482777-169482777 3:169764989-169764989
4 TERC NR_001566.1(TERC): n.110_113del deletion Pathogenic rs199422270 3:169482736-169482739 3:169764948-169764951
5 TERT NM_198253.2(TERT): c.2080G> A (p.Val694Met) single nucleotide variant Pathogenic rs121918662 5:1279456-1279456 5:1279341-1279341
6 TERT NM_198253.2(TERT): c.2315A> G (p.Tyr772Cys) single nucleotide variant Pathogenic rs121918663 5:1272367-1272367 5:1272252-1272252
7 PRF1 NM_001083116.3(PRF1): c.1163G> T (p.Ser388Ile) single nucleotide variant Pathogenic rs193302875 10:72358314-72358314 10:70598558-70598558
8 SBDS NM_016038.4(SBDS): c.258+1G> C single nucleotide variant Pathogenic rs113993992 7:66459198-66459198 7:66994211-66994211
9 TINF2 NM_012461.3(TINF2): c.862T> C (p.Phe288Leu) single nucleotide variant Pathogenic rs199422317 14:24709824-24709824 14:24240618-24240618
10 TERT NM_198253.2(TERT): c.2147C> T (p.Ala716Val) single nucleotide variant Pathogenic rs199422298 5:1278895-1278895 5:1278780-1278780
11 TERT NM_198253.2(TERT): c.2537A> G (p.Tyr846Cys) single nucleotide variant Pathogenic rs199422302 5:1268680-1268680 5:1268565-1268565
12 TERT NM_198253.2(TERT): c.2628C> G (p.His876Gln) single nucleotide variant Pathogenic rs199422303 5:1266605-1266605 5:1266490-1266490
13 TERC NR_001566.1(TERC): n.117A> C single nucleotide variant Pathogenic rs199422273 3:169482732-169482732 3:169764944-169764944
14 TERC NR_001566.1(TERC): n.178G> A single nucleotide variant Pathogenic rs199422275 3:169482671-169482671 3:169764883-169764883
15 TERC NR_001566.1(TERC): n.180C> T single nucleotide variant Pathogenic rs199422276 3:169482669-169482669 3:169764881-169764881
16 LOC110806306 ; TERC NR_001566.1(TERC): n.28_34del deletion Pathogenic rs199422259 3:169482815-169482821 3:169765027-169765033
17 TERC NR_001566.1(TERC): n.305G> A single nucleotide variant Pathogenic rs199422279 3:169482544-169482544 3:169764756-169764756
18 TERC NR_001566.1(TERC): n.322G> A single nucleotide variant Pathogenic rs199422280 3:169482527-169482527 3:169764739-169764739
19 TERC NR_001566.1(TERC): n.323C> T single nucleotide variant Pathogenic rs199422281 3:169482526-169482526 3:169764738-169764738
20 TERC NR_001566.1(TERC): n.391_392del deletion Pathogenic rs199422283 3:169482457-169482458 3:169764669-169764670
21 TERT NM_198253.2(TERT): c.3043T> C (p.Cys1015Arg) single nucleotide variant Pathogenic rs199422307 5:1255516-1255516 5:1255401-1255401
22 NBN NM_002485.4(NBN): c.1903A> T (p.Lys635Ter) single nucleotide variant Pathogenic/Likely pathogenic rs587782545 8:90960063-90960063 8:89947835-89947835
23 NBN NM_002485.4(NBN): c.2140C> T (p.Arg714Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730881864 8:90955525-90955525 8:89943297-89943297
24 NBN NM_002485.4(NBN): c.1030C> T (p.Gln344Ter) single nucleotide variant Pathogenic/Likely pathogenic rs767215758 8:90971047-90971047 8:89958819-89958819
25 IFNG NM_000619.2(IFNG): c.115-484_115-457CA[12] short repeat risk factor rs34079299 12:68552496-68552497 12:68158716-68158717
26 TERT NM_198253.2(TERT): c.1317_1319GGA[2] (p.Glu441del) short repeat Conflicting interpretations of pathogenicity rs377639087 5:1293676-1293678 5:1293561-1293563
27 TERT NM_198253.2(TERT): c.2775C> T (p.His925=) single nucleotide variant Conflicting interpretations of pathogenicity rs34528119 5:1264587-1264587 5:1264472-1264472
28 NBN NM_002485.4(NBN): c.425A> G (p.Asn142Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs769414 8:90993017-90993017 8:89980789-89980789
29 NBN NM_002485.4(NBN): c.595C> T (p.Pro199Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs587780097 8:90983508-90983508 8:89971280-89971280
30 TERT NM_198253.2(TERT): c.3184G> A (p.Ala1062Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs35719940 5:1254594-1254594 5:1254479-1254479
31 NBN NM_002485.4(NBN): c.1262T> C (p.Leu421Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs104895032 8:90967646-90967646 8:89955418-89955418
32 NBN NM_002485.4(NBN): c.628G> T (p.Val210Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs61754796 8:90983475-90983475 8:89971247-89971247
33 NBN NM_002485.4(NBN): c.1999T> C (p.Ser667Pro) single nucleotide variant Conflicting interpretations of pathogenicity rs587780091 8:90958439-90958439 8:89946211-89946211
34 TERT NM_198253.2(TERT): c.604G> A (p.Ala202Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs121918661 5:1294397-1294397 5:1294282-1294282
35 NBN NM_002485.4(NBN): c.511A> G (p.Ile171Val) single nucleotide variant Conflicting interpretations of pathogenicity rs61754966 8:90990521-90990521 8:89978293-89978293
36 TERT NM_198253.2(TERT): c.2654+10G> A single nucleotide variant Conflicting interpretations of pathogenicity rs375473823 5:1266569-1266569 5:1266454-1266454
37 TERT NM_198253.2(TERT): c.3150G> C (p.Lys1050Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs373400596 5:1255409-1255409 5:1255294-1255294
38 TERT NM_198253.2(TERT): c.663G> T (p.Ala221=) single nucleotide variant Conflicting interpretations of pathogenicity rs35837567 5:1294338-1294338 5:1294223-1294223
39 IFNG NM_000619.3(IFNG): c.-5A> G single nucleotide variant Uncertain significance rs181407537 12:68553400-68553400 12:68159620-68159620
40 IFNG NM_000619.3(IFNG): c.-34T> G single nucleotide variant Uncertain significance rs752463155 12:68553429-68553429 12:68159649-68159649
41 IFNG NM_000619.3(IFNG): c.*9C> T single nucleotide variant Uncertain significance rs886049801 12:68549124-68549124 12:68155344-68155344
42 IFNG NM_000619.3(IFNG): c.-2C> A single nucleotide variant Uncertain significance rs886049802 12:68553397-68553397 12:68159617-68159617
43 IFNG NM_000619.3(IFNG): c.-9T> C single nucleotide variant Uncertain significance rs886049803 12:68553404-68553404 12:68159624-68159624
44 NBN NM_002485.4(NBN): c.390A> G (p.Gln130=) single nucleotide variant Uncertain significance 8:90993052-90993052 8:89980824-89980824
45 IFNG NM_000619.3(IFNG): c.431C> A (p.Ser144Ter) single nucleotide variant Uncertain significance 12:68549203-68549203 12:68155423-68155423
46 NBN NM_002485.4(NBN): c.361G> C (p.Asp121His) single nucleotide variant Uncertain significance rs777916019 8:90993081-90993081 8:89980853-89980853
47 TERT NM_198253.2(TERT): c.3191C> T (p.Pro1064Leu) single nucleotide variant Uncertain significance rs886059831 5:1254587-1254587 5:1254472-1254472
48 TERT NM_198253.2(TERT): c.880C> T (p.His294Tyr) single nucleotide variant Uncertain significance rs886059906 5:1294121-1294121 5:1294006-1294006
49 IFNG NM_000619.3(IFNG): c.*107A> G single nucleotide variant Uncertain significance rs886049800 12:68549026-68549026 12:68155246-68155246
50 IFNG NM_000619.3(IFNG): c.*500C> T single nucleotide variant Uncertain significance rs528060683 12:68548633-68548633 12:68154853-68154853

UniProtKB/Swiss-Prot genetic disease variations for Aplastic Anemia:

# Symbol AA change Variation ID SNP ID
1 TERT p.His412Tyr VAR_025149 rs34094720
2 TERT p.Ala202Thr VAR_036863 rs121918661
3 TERT p.Val694Met VAR_036866 rs121918662
4 TERT p.Lys570Asn VAR_062536
5 TERT p.Gly682Asp VAR_062537 rs199422295
6 TERT p.Thr726Met VAR_062539 rs149566858
7 TERT p.Arg631Gln VAR_062783 rs199422294
8 TERT p.Pro785Leu VAR_062784 rs483352771

Expression for Aplastic Anemia

Search GEO for disease gene expression data for Aplastic Anemia.

Pathways for Aplastic Anemia

Pathways related to Aplastic Anemia according to KEGG:

# Name Kegg Source Accession
1 Osteoclast differentiation hsa04380
2 Antigen processing and presentation hsa04612

Pathways related to Aplastic Anemia according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
12.32 PRF1 IL3 IFNG CSF2
Show member pathways
Show member pathways
Show member pathways
8 11.69 IL3 IFNG EPO
9 11.69 SBDS NOP10 NHP2 DKC1
Show member pathways
11.58 IL3 IFNG CSF2
12 11.37 KITLG IL3 EPO
14 11.3 KITLG IL3 EPO CSF2
16 11.04 IL3 IFNG CSF2
Show member pathways

GO Terms for Aplastic Anemia

Cellular components related to Aplastic Anemia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 nuclear chromosome, telomeric region GO:0000784 9.73 TINF2 TERT NHP2 NBN
2 Cajal body GO:0015030 9.67 TERC NOP10 NHP2 DKC1
3 chromosome, telomeric region GO:0000781 9.62 TINF2 TERT TERC NBN
4 small nucleolar ribonucleoprotein complex GO:0005732 9.48 NOP10 NHP2
5 nuclear telomere cap complex GO:0000783 9.46 TINF2 TERT
6 box H/ACA snoRNP complex GO:0031429 9.43 NOP10 NHP2 DKC1
7 telomerase catalytic core complex GO:0000333 9.4 TERT TERC
8 box H/ACA scaRNP complex GO:0072589 9.33 NOP10 NHP2 DKC1
9 box H/ACA telomerase RNP complex GO:0090661 9.26 TERC NOP10 NHP2 DKC1
10 telomerase holoenzyme complex GO:0005697 9.02 TERT TERC NOP10 NHP2 DKC1
11 extracellular region GO:0005576 10.15 THPO PRF1 KITLG IL3 IFNG EPO
12 nucleolus GO:0005730 10.05 TERT SBDS RPL5 NOP10 NHP2 NBN

Biological processes related to Aplastic Anemia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.93 THPO KITLG IL3 IFNG EPO CSF2
2 ribosome biogenesis GO:0042254 9.73 SBDS NOP10 NHP2 DKC1
3 cell proliferation GO:0008283 9.71 THPO SBDS NBN EPO
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 IL3 IFNG EPO CSF2
5 rRNA processing GO:0006364 9.65 SBDS RPL5 NOP10 NHP2 DKC1
6 positive regulation of Ras protein signal transduction GO:0046579 9.55 KITLG EPO
7 embryonic hemopoiesis GO:0035162 9.54 KITLG IL3
8 pseudouridine synthesis GO:0001522 9.52 NOP10 DKC1
9 positive regulation of interleukin-23 production GO:0032747 9.51 IFNG CSF2
10 positive regulation of telomerase RNA localization to Cajal body GO:1904874 9.5 NOP10 NHP2 DKC1
11 positive regulation of hematopoietic stem cell proliferation GO:1902035 9.49 THPO KITLG
12 positive regulation of killing of cells of other organism GO:0051712 9.48 PRF1 IFNG
13 snRNA pseudouridine synthesis GO:0031120 9.33 NOP10 NHP2 DKC1
14 rRNA pseudouridine synthesis GO:0031118 9.13 NOP10 NHP2 DKC1
15 telomere maintenance via telomerase GO:0007004 9.02 TERT TERC NOP10 NHP2 DKC1

Molecular functions related to Aplastic Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.67 THPO KITLG IL3 CSF2
2 cytokine activity GO:0005125 9.63 THPO KITLG IL3 IFNG EPO CSF2
3 telomerase activity GO:0003720 9.43 TERT TERC DKC1
4 RNA-directed DNA polymerase activity GO:0003964 9.4 TERT TERC
5 telomerase RNA reverse transcriptase activity GO:0003721 9.32 TERT TERC
6 box H/ACA snoRNA binding GO:0034513 9.13 NOP10 NHP2 DKC1
7 telomerase RNA binding GO:0070034 8.92 TERT NOP10 NHP2 DKC1
8 protein binding GO:0005515 10.36 TINF2 TERT TERC SBDS RPL5 PRF1

Sources for Aplastic Anemia

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....